Search

Displaying results 1751 - 1760 of 10000 in total
  1. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

  2. Drug

    Asparaginase Erwinia chrysanthemi

    go.drugbank.com/drugs/DB08886
    ApprovedInvestigational

    Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. … It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death.

  3. Drug

    Thrombin alfa

    go.drugbank.com/drugs/DB11572
    Approved

    Thrombin Alfa precursor is secreted to culture medium as single chain form that is proteolytically converted to a two-chain active form (using a protein derived from snakes) and is purified by a chromatographic … Thrombin Alfa is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line.

  4. Drug

    Almitrine

    go.drugbank.com/drugs/DB01430
    Approved

    Almitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. … It is also reported to have a potentially beneficial effect in treating the noctural oxygen desaturation without impairing the quality of sleep.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Golimumab

    go.drugbank.com/drugs/DB06674
    ApprovedInvestigational

    Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate … treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe

    Categories: Agents reducing cytokine levelsProducts: SIMPONI 50 MG ENJEKSİYONLUK COZELTİ ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADET, SIMPONI 50 MG ENJEKSİYONLUK COZELTİ ICEREN KULLANIMA HAZIR ENJEKTOR, 3 ADET
  6. Drug

    PRO 2000

    go.drugbank.com/drugs/DB05385
    Investigational

    PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. … It is being studied for the prevention of HIV infection and other sexually transmitted diseases.

    International brands: Lavelin FACategories: Compounds used in a research, industrial, or household setting
  7. Drug

    Penpulimab

    go.drugbank.com/drugs/DB16747
    ApprovedInvestigational

    The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events. … Penpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1).

  8. Drug

    Chromium gluconate

    go.drugbank.com/drugs/DB14528
    Approved

  9. Drug

    Chromium nicotinate

    go.drugbank.com/drugs/DB14529
    Approved

  10. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    The LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD … Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA).